Amina Rakisheva

Dr. Amina Rakisheva

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2025 in European Heart Journal
Verified
Journal Article
Closed access
JBJulie De Backer
Julie De Backer
Kristina Hermann HaugaaKristina Hermann Haugaa
Kristina Hermann Haugaa
NHNina Eide Hasselberg
Nina Eide Hasselberg
MHMichèle de Hosson
Michèle de Hosson
MBMargarita Brida
Margarita Brida
FZFeruza Zakirova
Feruza Zakirova

23 May 2020 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
ARAmina Rakisheva
Amina Rakisheva
Maria E. MarketouMaria E. Marketou
Maria E. Marketou
AKAnna Klimenko
Anna Klimenko
TTTatyana Troyanova‐Shchutskaia
Tatyana Troyanova‐Shchutskaia
PVPanos Vardas
Panos Vardas
Hyperkalemia is a frequent and sometimes life‐threatening condition that may be associated with arrhythmia and cardiac dysfunction in patients with heart failure (HF). High potassium levels in HF represent both a direct risk for cardiovascular complication and an indirect biomarker of the severity of the underlying disease, reflecting neurohormonal activation and renal dysfunction. Evaluating the prevalence and significance of hyperkalemia in HF patients is essential for optimizing the use of potassium sparing agents, such the renin–angiotensin–aldosterone system inhibitors (RAASi) or angiotensin receptor‐neprilysin inhibitors and mineralocorticoid receptor antagonists, which represent a well‐established cornerstone and life‐saving therapy. In this review we discuss recent findings and current concepts related to the epidemiology, pathological mechanisms and implications of hyperkalemia, as well as novel therapeutic approaches to counteract it in patients with HF. The balance between optimizing life‐saving potassium sparing medication and minimizing hyperkalemia‐associated risk is much needed in patients with HF. Although older potassium‐binding agents are associated with serious adverse events, novel potassium‐binding drugs are effective in lowering potassium levels and are generally well tolerated. Novel potassium‐binding drugs, such as patiromer and sodium zirconium cyclosilicate, may help to optimize therapy in HF and achieve guideline‐recommended doses. Hyperkalemia is common in HF patients and is associated with a poorer prognosis and an increased risk of cardiovascular complications: Contrariwise, “moderate” potassium levels go with a better prognosis, while the emergence of new drugs, potassium binders, could allow target doses of RAASi to be achieved.

11 September 2024 in Cardiac Failure Review
Verified
Journal Article
Open access
PDF file
ASAnastasia Shchendrygina
Anastasia Shchendrygina
ARAmina Rakisheva
Amina Rakisheva
IGIlya Giverts
Ilya Giverts
YRYasmin Rustamova
Yasmin Rustamova
ASAnzhela Soloveva
Anzhela Soloveva
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are emerging glucose-lowering agents primarily used in managing diabetes and obesity. Recently, GLP-1 RAs have garnered attention for their cardiovascular benefits beyond glycaemic control in patients with type 2 diabetes, exhibiting patterns previously seen in cardiovascular outcomes trials on sodium–glucose cotransporter 2 inhibitors, which now receive a high level of recommendation for the treatment of heart failure (HF). GLP-1 RAs have been increasingly investigated in HF cohorts, but mainly in small-scale studies reporting inconclusive findings regarding clinical outcomes and different safety profiles in HF patients with reduced and preserved ejection fractions. This review discusses the effects of GLP-1 RAs on surrogate HF outcomes, such as cardiac structure and function, exercise capacity and quality of life, in HF patients across the spectrum of left ventricular ejection fraction, to provide insights into the potential of these agents to be investigated in large clinical trials to evaluate clinical outcomes.

21 March 2025 in European Heart Journal
Verified
Journal Article
Closed access
EAEmanuele Di Angelantonio
Emanuele Di Angelantonio
LPLisa Pennells
Lisa Pennells
MAMagdy Abdelhamid
Magdy Abdelhamid
VAVictor Aboyans
Victor Aboyans
RARiccardo Asteggiano
Riccardo Asteggiano
EPEva B Prescott
Eva B Prescott
The level of evidence (LOE) grading system for European Society of Cardiology (ESC) Clinical Practice Guidelines (CPG) classifies the quality of the evidence supporting a recommendation. However, the current taxonomy does not fully consider the optimal study design necessary to establish evidence for different types of recommendations in ESC guidelines. Therefore, two separate task forces of clinical and methodological experts were appointed by the CPG Committee, with the first tasked with updating the LOE grading system for therapy and prevention and the second responsible for developing a LOE grading system for diagnosis and prediction. This report from the second of these Task Forces develops a new system for diagnostic tests and prediction models which maintains the three-level grading structure to classify the quality of the evidence but introduces new definitions specific for diagnosis and prediction. For diagnostic tests, LOE A represents conclusive evidence of adequate diagnostic ability from at least two high-quality studies. Level of evidence B represents suggestive evidence from one high-quality or at least two moderate-quality studies. Level of evidence C represents preliminary evidence not classified as A or B, including evidence from less than two moderate-quality studies, or from expert consensus. For prediction models, LOE A represents conclusive evidence of adequate predictive ability from at least one high-quality derivation and two or more external validation studies of at least moderate quality. Level of evidence B represents suggestive evidence in one or more derivation studies and one or more external validation studies of at least moderate quality. Level of evidence C represents preliminary evidence not classified as A or B, including evidence from a derivation study of at least moderate quality, but with low quality or no external validation, or a derivation study of low quality.

17 June 2025 in Heart, Lung and Circulation
Verified
Journal Article
Open access
VCVijay Chopra
Vijay Chopra
MKMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
MAMagdy Abdelhamid
Magdy Abdelhamid
WAWilliam T. Abraham
William T. Abraham
OAOffer Amir
Offer Amir
SZShelley Zieroth
Shelley Zieroth
Inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices as well as practical and political issues restrict the global applicability of currently available guidelines. There is a need for universal recommendations that address the unique challenges faced by patients and healthcare providers worldwide. Our iCARDIO Alliance Global Implementation Guidelines emphasize the incorporation of novel therapies, while integrating standard of care with the most up-to-date evidence to enable clinicians to optimize patient care. This document is about heart failure (HF), including acute and chronic heart failure, heart failure with reduced ejection fraction and heart failure with preserved ejection fraction as well as cardiomyopathies. Context-specific recommendations tailored to individual patient needs are highlighted providing a thorough evaluation of the risks, benefits, and overall value of each therapy, aiming to establish a standard of care that improves patient outcomes and reduces the burden of hospitalization in this susceptible population. These guidelines provide evidence-based recommendations that represent a group consensus considering the many other published guidelines that have reviewed many of the issues discussed here, but they also make new recommendations where new evidence has recently emerged. Most importantly these guidelines also provide recommendations on a number of issues where resource limitations may put constraints on the care provided to HF patients. Such "economic adjustment" recommendations aim to provide guidance for situations when "Resources are somewhat limited" or when "Resources are severely limited". Hence, this document presents not only a comprehensive but also concise update to HF management guidelines thereby aiming to provide a unified strategy for the pharmacological, non-pharmacological, invasive and interventional management of this significant global health challenge that is applicable to the needs of healthcare around the globe.

1 January 2024 in International Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
ARAmina Rakisheva
Amina Rakisheva
ASAnzhela Soloveva
Anzhela Soloveva
ASAnastasia Shchendrygina
Anastasia Shchendrygina
IGIlya Giverts
Ilya Giverts
Rakisheva A, et al. Int J Heart Fail. 2024 Jul;6(3):93-106. https://doi.org/10.36628/ijhf.2023.0064